Back to Authors

Yeung, Paul

A5109836311 | I4210139373

Mayo Clinic

Teva Pharmaceuticals (United States)

Citations 9

Efficacy of Two Dose Regimens of Subcutaneous Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine (S32.005)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s32.005

Efficacy Of Fremanezumab in Patients With Chronic Migraine With or Without Concomitant Use of Preventive Medication (P4.099)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p4.099

Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine (P4.093)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p4.093

Long-Term Efficacy of Fremanezumab in Patients Who Reverted From a Chronic to an Episodic Migraine Classification (S17.006)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.s17.006

Impact of Fremanezumab on Response Rates, Acute Medication Use, and Disability in Patients With Episodic Migraine Who Have Failed at Least One Prior Migraine Preventive Medication (P2.10-001)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.p2.10-001

Improvement in Response Over Time With Fremanezumab in Patients Who Reverted From a Chronic to an Episodic Migraine Classification (P1.10-013)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.p1.10-013

Efficacy of Fremanezumab in Migraine Patients Who Have Failed at Least One Prior Migraine Preventive Medication (P1.10-011)

Neurology | December 7, 2023 | Volume: 92 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.92.15_supplement.p1.10-011

Long-term safety, tolerability, and efficacy of fremanezumab in migraine

Neurology | September 11, 2020 | Volume: 95 | Issue: 18 | Pages: No page available

10.1212/wnl.0000000000010600 | PMID 32913018

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

JAMA | May 17, 2018 | Volume: 319 | Issue: 19 | Pages: 1999

10.1001/jama.2018.4853 | PMID 29800211